How SpringWorks Took Pfizer’s Rare Disease Ghost Drug and Got It to Patients

SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for neurofibromatosis alive. This method could work for “every rare disease under the sun,” advocates say.

Scroll to Top